	US 12,421,302 B2
	CAR-t cells and autoimmune diseases
Jeffrey A. Bluestone, San Francisco, CA (US); and Caroline Raffin, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/968,794
Filed by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
PCT Filed Feb. 11, 2019, PCT No. PCT/US2019/017532 § 371(c)(1), (2) Date Aug. 10, 2020, PCT Pub. No. WO2019/157461, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/629,103, filed on Feb. 11, 2018.
Prior Publication US 2020/0399355 A1, Dec. 24, 2020
Int. Cl. C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61P 19/02 (2006.01); A61P 37/06 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)

CPC C07K 16/18 (2013.01) [A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 40/11 (2025.01); A61K 40/22 (2025.01); A61K 40/31 (2025.01); A61K 40/416 (2025.01); A61P 19/02 (2018.01); A61P 37/06 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); A61K 2035/124 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01)]

20 Claims

1. A chimeric antigen receptor (CAR) comprising an antigen specific binding domain, a hinge domain, a transmembrane domain, co-stimulatory domain, and a CD3ζ signaling domain, wherein the antigen specific binding domain specifically binds to antigens comprising citrullinated-vimentin (CV) polypeptides or peptides thereof having the amino acid sequence of SEQ ID NO: 21 or 22, and wherein the co-stimulatory domain comprises a CD28 or a 41BB polypeptide, and wherein the antigen binding domain comprises a single chain variable fragment (scFv) which specifically binds to citrullinated-vimentin (CV), wherein the scFv comprises the complementarity determining region (CDR) sequences of SEQ ID NO:15.